Dr. Motzer on Nivolumab Versus Everolimus in Renal Call Carcinoma

Robert J. Motzer, MD
Published: Wednesday, Jan 18, 2017

>br>

Robert J. Motzer, MD, attending physician, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, and professor of Medicine, Weill Medical College, Cornell University, discusses the FDA approval of nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC).

Nivolumab was studied in a pivotal phase III trial for patients who had progressed on drugs like sunitinib (Sutent) and pazopanib (Votrient). The primary endpoint was overall survival (OS), which was reached, showing an OS benefit for nivolumab compared with everolimus, establishing it as a new standard of care.

Nivolumab had a higher response rate than everolimus, many of the responses being durable, with a median rate being 12 months. There was no improvement in progression-free survival, Motzer explains, which could be due to pseudo progression—when the tumor gets larger—or the mechanism of immunotherapy could be different then VEGF-targeted therapies, leading to delayed responses.

SELECTED
LANGUAGE
>br>

Robert J. Motzer, MD, attending physician, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, and professor of Medicine, Weill Medical College, Cornell University, discusses the FDA approval of nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC).

Nivolumab was studied in a pivotal phase III trial for patients who had progressed on drugs like sunitinib (Sutent) and pazopanib (Votrient). The primary endpoint was overall survival (OS), which was reached, showing an OS benefit for nivolumab compared with everolimus, establishing it as a new standard of care.

Nivolumab had a higher response rate than everolimus, many of the responses being durable, with a median rate being 12 months. There was no improvement in progression-free survival, Motzer explains, which could be due to pseudo progression—when the tumor gets larger—or the mechanism of immunotherapy could be different then VEGF-targeted therapies, leading to delayed responses.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x